Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential
Cantor Fitzgerald reiterated an Overweight rating and $37 price target for Zai Lab (ZLAB), citing potential for its DLL3 ADC, zocilurtatug, in small cell lung cancer. The stock is up 45% year-to-date. Zai Lab's Q2 earnings beat expectations with $106.3M revenue and adjusted EPS of -$0.05. Analysts maintain a Strong Buy consensus with price targets ranging from $24.25 to $50.
How this was made
The 30-second read
Why it matters
The note may sustain investor interest but is unlikely to trigger a large move given the stock's recent rally.
Market read
Analyst rating reiteration provides modest trading relevance for Zai Lab shareholders.
What to watch
Potential competition from other ADC pipelines and the need for longer PFS to sustain upside.
Background
Cantor Fitzgerald issued an analyst note reiterating its Overweight stance on Zai Lab, citing recent trial data and a competitor's ADC withdrawal.
Ticker impact
Cantor Fitzgerald reiterated an Overweight rating and set a $37 price target for Zai Lab.
likely modest upward pressure as the rating supports the stock.
The rating and target are new analyst commentary, but the stock has already rallied strongly; impact is limited.
Market effects
Reinforces positive sentiment for biotech ADC developers.
Limited to US-listed biotech investors.
Minor, as the news is company‑specific.
Counterpoint
The stock may be overvalued despite the rating, given its 45% YTD gain.
Key entities
- companyZai Lab
US‑listed biotech developing antibody‑drug conjugates.
- analystCantor Fitzgerald
Equity research firm providing the rating.
